Core Viewpoint - Zhaoke Ophthalmology-B (06622) has seen a stock price increase of over 5%, currently trading at HKD 3.79, with a transaction volume of HKD 6.119 million, following the announcement of FDA approval for its eye drop product [1] Group 1: FDA Approval and Product Details - Zhaoke Ophthalmology announced that its partner, Tenpoint Therapeutics, has received FDA approval for the commercialization of Carbachol and Bromonidine Tartrate Eye Drops (2.75%/0.1%) [1] - The eye drop, known as BRIMOCHOL PF during clinical trials, will be marketed in the U.S. under the name YUVEZZI, aimed at treating presbyopia [1] Group 2: Commercial Strategy and Partnerships - The FDA approval is considered a strong catalyst for Zhaoke Ophthalmology as it formulates its commercialization strategy [1] - The company has established a partnership network for BRIMOCHOL PF, which currently includes eight commercial partners across the Asia-Pacific region (including South Korea, Australia, New Zealand, Thailand, Indonesia, Taiwan/Hong Kong/Macau, Singapore, and Vietnam) and the Middle East [1] - With FDA recognition, Zhaoke anticipates accelerating the market launch of the drug, marking a significant global milestone [1]

Core Viewpoint - Tenpoint Therapeutics, Ltd. has received FDA approval for the commercialization of BRIMOCHOL PF, an innovative eye drop treatment for presbyopia, which will be marketed as YUVEZZI in the U.S. [1] Group 1 - The approval follows the successful completion of Phase 3 clinical trials, with the first key Phase 3 study (BRIO I) demonstrating the combination therapy's superiority over individual therapies [1] - The second Phase 3 study (BRIO II) achieved all primary endpoints for near vision improvement, showing a statistically significant increase in binocular uncorrected near visual acuity (BUCNVA) by three lines or more, while binocular uncorrected distance visual acuity (BUCDVA) did not decrease by one line or more [1] Group 2 - During the BRIO II study, BRIMOCHOL PF showed good tolerability with no serious treatment-related adverse events reported, and the incidence of eye redness was low [2] - The report rate of eye redness for subjects receiving BRIMOCHOL PF was 2.8%, significantly lower than the 10.7% for those receiving only carbachol [2] Group 3 - This FDA approval serves as a strong catalyst for the company's commercialization strategy, with a partnership network established across the Asia-Pacific region and the Middle East, including eight commercial partners [2] - With FDA recognition, the company anticipates accelerating the market entry of BRIMOCHOL PF, marking an important global milestone [2]

Core Insights - Tenpoint Therapeutics, Ltd. has received FDA approval for the commercialization of BRIMOCHOL PF (2.75%/0.1%), an innovative eye drop for the treatment of presbyopia, which will be marketed as YUVEZZI in the U.S. [1][2] Group 1: Clinical Trial Results - The approval follows the successful completion of Phase 3 clinical trials, with the first key Phase 3 study (BRIO I) demonstrating that the combination therapy is more effective than individual active drug compounds [1] - In the second placebo-controlled Phase 3 study (BRIO II), BRIMOCHOL PF met all primary endpoints for near vision improvement, showing a statistically significant increase in binocular uncorrected near visual acuity (BUCNVA) by three lines or more, while binocular uncorrected distance visual acuity (BUCDVA) did not decrease by one line or more [1] Group 2: Safety and Tolerability - During the monitoring of over 72,000 treatment days in the BRIO II study, BRIMOCHOL PF was well-tolerated, with no treatment-related serious adverse events observed [2] - The incidence of eye redness (conjunctival hyperemia) as a reported adverse event was low, with a rate of 2.8% in BRIMOCHOL PF recipients compared to 10.7% in those receiving only carbachol [2] Group 3: Commercial Strategy - The FDA approval serves as a strong catalyst for the company's commercialization strategy, as it has established a partnership network for BRIMOCHOL PF, including eight commercial partners across the Asia-Pacific region and the Middle East [2] - With FDA recognition, the company anticipates accelerating the market entry of the drug, marking a significant global milestone [2]